Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease

Elisa Cangiano, Caterina Cavazza, Gianluca Campo, Marco Valgimigli, Gloria Francolini, Patrizia Malagutti, Claudio Pratola, Roberto Ferrari

Research output: Contribution to journalArticlepeer-review

Abstract

To test the role of necrosis, ischemia or both inbone marrow cells (BMC) mobilization in patients with cardiovascular disease. We studied three groups of patients: group 1, Iatrogenic Necrosis, with pure necrosis (28 patients undergoing transcatheter radiofrequency ablation); group 2, Ischemic Necrosis (30 patients with myocardial infarction); group 3, Pure Ischemia (24 patients with unstable angina). As control groups, we studied 27 patients with stable coronary artery disease (CAD), and 20 patients without CAD undergoing angiography for valvular diseases or cardiomiopathy. CD34 ? cells and cytokines were evaluated at: T 0 (baseline), 48 h and 5, 7, 10, 14 days thereafter. We observed a significant increase of CD34 + cells at T 3 and T 4 only in Iatrogenic Necrosis and Ischemic Necrosis group. The peak of mobilization was observed ten days after the necrotic event (2.8 ± 1.4 vs. 5.9 ± 1.9 in the group 1, P = 0.03; and 3 ± 1.5 vs. 5.6 ± 2 in the group 2, P = 0.04; respectively). We found a good correlation between CD34 + and vascular endothelial growth factor (VEGF) and stromal derived factor (SDF-1a) peak values (r = 0.77 and r = 0.63, respectively). At multivariable analysis, myocardial necrosis (OR 3.5, 95%CI 2.2-4.2, P

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalJournal of Thrombosis and Thrombolysis
Volume32
Issue number1
DOIs
Publication statusPublished - Jul 2011

Keywords

  • Bone marrow cells
  • CD34 + cells
  • Cytokines
  • Stromal derived factor
  • Vascular endothelial factor

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease'. Together they form a unique fingerprint.

Cite this